LeMaitre Vascular (LMAT) Insider Form 4: Dividend Equivalents from RSU

Rhea-AI Filing Summary

LeMaitre Vascular Inc. (LMAT) Form 4: Dorian Paul LeBlanc, identified as Chief Financial Officer and a director, reported a transaction dated 09/04/2025. The filing records the acquisition of dividend equivalent rights that accrued on a restricted stock unit award originally granted on 03/10/2025. Each dividend equivalent right is the economic equivalent of one share of the company’s common stock. The report shows an acquisition at $0 and a post-transaction beneficial ownership figure of 8.4578 (direct). The form is signed on the filing by Nathan Ulrich on 09/08/2025.

Insights

Financial Analyst

TL;DR: A routine Form 4 records dividend-equivalent accruals from RSUs for the CFO, adding a small number of share equivalents at no cash cost.

The filing documents that dividend equivalent rights tied to a restricted stock unit award vested proportionately and were recorded as acquisitions on 09/04/2025 at no purchase price. The transaction increases the reporting person’s direct beneficial ownership to 8.4578 share-equivalents. This is a non-cash, compensation-related increase rather than an open-market purchase or sale, so it has limited immediate cash-flow or market-supply implications. The item provides transparency on insider holdings but does not present a material corporate finance event.

Corporate Governance Expert

TL;DR: Disclosure complies with Section 16 reporting of RSU dividend equivalents; it ensures insider transparency but is not materially impactful.

The Form 4 identifies the reporting person as the Chief Financial Officer and discloses dividend equivalent rights that accrued on an RSU awarded 03/10/2025 and recorded 09/04/2025. The document states each dividend equivalent equals one share and shows the acquisition at $0, consistent with compensation mechanics. The signature block shows filing authentication by Nathan Ulrich on 09/08/2025. From a governance perspective, the filing fulfills routine reporting obligations and provides investors visibility into executive compensation-related ownership changes.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider LeBlanc Dorian Paul

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Dividend Equivalent Rights	2.5281	$0.00	$0.00

Holdings After Transaction: Dividend Equivalent Rights — 8.4578 shares (Direct)

Footnotes (1)

1. F1. These dividend equivalent rights accrued on a restricted stock unit award granted on 3/10/2025 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

FAQ

What transaction did LMAT CFO Dorian Paul LeBlanc report on Form 4?

The Form 4 reports the acquisition of dividend equivalent rights that accrued on an RSU award, recorded on 09/04/2025.

How many share-equivalents did the reporting person own after the reported transaction?

The filing shows a post-transaction beneficial ownership of 8.4578 (direct).

What is the economic nature of the dividend equivalent rights noted in the filing?

Each dividend equivalent right is described as the economic equivalent of one share of the issuer’s common stock and accrued on an RSU granted 03/10/2025.

Was there a purchase price for the acquired dividend equivalents?

The Form 4 lists the acquisition price as $0, indicating these were recorded as compensation-related accruals rather than market purchases.

Who signed or certified the Form 4 filing and when?

The signature block shows /s/ Nathan Ulrich dated 09/08/2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 09/08/2025 - 06:18 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LeBlanc Dorian Paul

(Last) (First) (Middle)

C/O LEMAITRE VASCULAR, INC.

63 SECOND AVENUE

(Street)

BURLINGTON MA 01803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Dividend Equivalent Rights	(1)	09/04/2025		A		2.5281		(1)	(1)	Common Stock	2.5281	$0	8.4578	D

Explanation of Responses:

1. These dividend equivalent rights accrued on a restricted stock unit award granted on 3/10/2025 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

	/s/ Nathan Ulrich	09/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.